Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Pass Below Two Hundred Day Moving Average of $6.98 (2024)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.98 and traded as low as $5.08. Aurinia Pharmaceuticals shares last traded at $5.20, with a volume of 1,441,524 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Cantor Fitzgerald decreased their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Royal Bank of Canada dropped their price objective on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Finally, Jefferies Financial Group decreased their price objective on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating for the company in a research report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Check Out Our Latest Report on Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Price Performance

The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19. The stock has a fifty day moving average of $5.10 and a 200-day moving average of $6.98.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative return on equity of 15.06%. The company had revenue of $45.10 million during the quarter, compared to analysts’ expectations of $45.00 million. During the same period last year, the business earned ($0.18) earnings per share. The company’s quarterly revenue was up 58.8% on a year-over-year basis. On average, sell-side analysts predict that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC purchased a new position in Aurinia Pharmaceuticals during the 4th quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Aurinia Pharmaceuticals by 95.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,798 shares during the period. Tidemark LLC acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $39,000. DekaBank Deutsche Girozentrale purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter valued at $65,000. Finally, Eagle Asset Management Inc. acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth $92,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

(Get Free Report)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Featured Stories

• Five stocks we like better than Aurinia Pharmaceuticals
• 5 discounted opportunities for dividend growth investors
• Jack in the Box Bottoms and the Rebound is on
• What is the Euro STOXX 50 Index?
• On Shares Move Higher in Race to a New All-Time High
• Dividend Payout Ratio Calculator
• What Wall Street Doesn’t Want You to Know About Alibaba Stock

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.